The Viral Hemorrhagic Fever Consortium was established in 2010 as a result of a five-year $15 million contract awarded to Tulane University by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). This contract was awarded for Tulane’s ongoing efforts to treat and prevent Lassa Fever, a disease that threatens hundreds of thousands of lives annually in West Africa and is classified as a potential bioterrorism threat.

Mission

The goal of the Consortium is to understand mechanisms related to the human immune response to Lassa virus infection. Specifically, by understanding what parts of the virus are recognized by the immune system, we can better understand mechanisms of antibody-mediated protection or pathogenesis in humans with Lassa Fever.
Consortium History

Since the consortium’s beginning it has grown to encompass more than just research to better understand the Lassa Virus. The consortium works to discover ways to treat and prevent Lassa Virus and expanded its scope to include Ebola, Marburg, and other Arenaviruses that are of great concern to public health and bioterrorism.

Structure & Governance

The consortium is overseen by Tulane University.

Financing

The consortium was awarded a 5-year, $15 million grant by the National Institute of Allergy and Infectious Disease, which is part of the NIH.

Patent Engagement

During the Human Evolution Project, the consortium engaged patients to study genome biomarkers that would be useful in understanding the Lassa Virus.

Impact/Accomplishment

For news relating to the consortium, click here.
Links/Social Media Feed

Homepage  http://www.vhfc.org/consortium

Points of Contact

http://www.vhfc.org/contact

Dr. Robert Garry
Professor
Department of Microbiology & Immunology
Tulane University Health Sciences Center
1430 Tulane Avenue, SL-38
New Orleans, LA, 70112
Phone: (504) 988-2027
rgarry@tulane.edu

Sponsors & Partners

Tulane
Scripps Research Institute
Broad Institute
Harvard University
University of California at San Diego
University of Texas Medical Branch
Autoimmune Technologies LLC
Corgenix Medical Corporation
Kenema Government Hospital (Sierra Leone)
Irruna Specialist Teaching Hospital (Nigeria)

Updated: 06/26/2017